| Melissa Kathleen Colbert, DO | |
|
1921 Stonecipher Dr, Ada, OK 74820-3439 | |
| (580) 421-3980 | |
| Not Available |
| Full Name | Melissa Kathleen Colbert |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 1921 Stonecipher Dr, Ada, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093000184 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 2018577 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chickasaw Nation Medical Center | Ada, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chickasaw Nation Division Of Health | 8426957523 | 209 |
News Archive
Wait times for cancer radiation treatment continued their decline across Ontario during 2009, despite a more than 10 per cent increase in the number of patients receiving treatment, according to the 2010 Cancer System Quality Index report issued today.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer.
The incidence and mortality associated with hepatocellular carcinoma have been increasing worldwide, and hepatitis C virus infection plays an important role in the pathogenesis of HCC.
› Verified 9 days ago
| Entity Name | Chickasaw Nation Division Of Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255364923 PECOS PAC ID: 8426957523 Enrollment ID: O20040108000364 |
News Archive
Wait times for cancer radiation treatment continued their decline across Ontario during 2009, despite a more than 10 per cent increase in the number of patients receiving treatment, according to the 2010 Cancer System Quality Index report issued today.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer.
The incidence and mortality associated with hepatocellular carcinoma have been increasing worldwide, and hepatitis C virus infection plays an important role in the pathogenesis of HCC.
› Verified 9 days ago
| Entity Name | Questcare Medical Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164574489 PECOS PAC ID: 6204739402 Enrollment ID: O20040127000697 |
News Archive
Wait times for cancer radiation treatment continued their decline across Ontario during 2009, despite a more than 10 per cent increase in the number of patients receiving treatment, according to the 2010 Cancer System Quality Index report issued today.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer.
The incidence and mortality associated with hepatocellular carcinoma have been increasing worldwide, and hepatitis C virus infection plays an important role in the pathogenesis of HCC.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Kathleen Colbert, DO 1921 Stonecipher Dr, Ada, OK 74820-3439 Ph: (580) 421-4570 | Melissa Kathleen Colbert, DO 1921 Stonecipher Dr, Ada, OK 74820-3439 Ph: (580) 421-3980 |
News Archive
Wait times for cancer radiation treatment continued their decline across Ontario during 2009, despite a more than 10 per cent increase in the number of patients receiving treatment, according to the 2010 Cancer System Quality Index report issued today.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer.
The incidence and mortality associated with hepatocellular carcinoma have been increasing worldwide, and hepatitis C virus infection plays an important role in the pathogenesis of HCC.
› Verified 9 days ago
Crystalle M Evans, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Dr, Ada, OK 74820 Phone: 580-421-4526 | |
Dr. Christopher Goodwill, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Dr, Ada, OK 74820 Phone: 580-436-3980 Fax: 580-421-6283 | |
Mr. Joshua Medved, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Blvd, Ada, OK 74820 Phone: 580-421-4570 | |
Preston Hucks, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1921 Stonecipher Blvd, Ada, OK 74820 Phone: 580-421-4570 | |
Connie Marie Wilson, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Blvd, Ada, OK 74820 Phone: 580-421-4570 | |
Kent Denson, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 905 Colony Dr, Ada, OK 74820 Phone: 580-436-5111 Fax: 580-272-5731 |